<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pharmjournal</journal-id><journal-title-group><journal-title xml:lang="ru">Разработка и регистрация лекарственных средств</journal-title><trans-title-group xml:lang="en"><trans-title>Drug development &amp; registration</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2305-2066</issn><issn pub-type="epub">2658-5049</issn><publisher><publisher-name>LLC «CPHA»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33380/2305-2066-2024-13-3-1749</article-id><article-id custom-type="elpub" pub-id-type="custom">pharmjournal-1892</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>МЕТОДЫ АНАЛИЗА ЛЕКАРСТВЕННЫХ СРЕДСТВ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ANALYTICAL METHODS</subject></subj-group></article-categories><title-group><article-title>Разработка и валидация методики количественного определения субстанции аморфного дарунавира методом УФ-спектрофотометрии</article-title><trans-title-group xml:lang="en"><trans-title>Development and validation of UV-spectrophotometry method for quantitative determination of amorphous darunavir</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3558-9615</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мандрик</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Mandrik</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>119991, г. Москва, ул. Трубецкая, д. 8, стр. 2; 119991, г. Москва, Ленинский проспект, д. 29</p></bio><bio xml:lang="en"><p>8/2, Trubetskaya str., Mosсow, 119991; 29, Leninsky Prospekt, Moscow, 119991</p></bio><email xlink:type="simple">mandrik_m_a@staff.sechenov.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8375-9909</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Садковский</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Sadkovskii</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>119991, г. Москва, ул. Трубецкая, д. 8, стр. 2; 119991, г. Москва, Ленинский проспект, д. 29</p></bio><bio xml:lang="en"><p>8/2, Trubetskaya str., Mosсow, 119991; 29, Leninsky Prospekt, Moscow, 119991</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-7890-0821</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пинегина</surname><given-names>Е. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Pinegina</surname><given-names>E. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>119991, г. Москва, ул. Трубецкая, д. 8, стр. 2</p></bio><bio xml:lang="en"><p>8/2, Trubetskaya str., Mosсow, 119991</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5919-1866</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Король</surname><given-names>Л. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Korol</surname><given-names>L. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>119991, г. Москва, ул. Трубецкая, д. 8, стр. 2</p></bio><bio xml:lang="en"><p>8/2, Trubetskaya str., Mosсow, 119991</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7242-2988</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Краснюк</surname><given-names>И. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Krasnuk</surname><given-names>I. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>119991, г. Москва, ул. Трубецкая, д. 8, стр. 2</p></bio><bio xml:lang="en"><p>8/2, Trubetskaya str., Mosсow, 119991</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное автономное образовательное учреждение высшего образования «Первый Московский государственный медицинский университет имени И. М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет); Федеральное государственное бюджетное учреждение науки Ордена Трудового Красного Знамени Институт нефтехимического синтеза им. А. В. Топчиева Российской академии наук (ИНХС РАН)</institution></aff><aff xml:lang="en"><institution>I. M. Sechenov First MSMU of the Ministry of Health of the Russian Federation (Sechenov University); A. V. Topchiev Institute of Petrochemical Synthesis, RAS (TIPS RAS)</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Федеральное государственное автономное образовательное учреждение высшего образования «Первый Московский государственный медицинский университет имени И. М. Сеченова» Министерства здравоохранения Российской Федерации (Сеченовский Университет)</institution></aff><aff xml:lang="en"><institution>I. M. Sechenov First MSMU of the Ministry of Health of the Russian Federation (Sechenov University)</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>09</day><month>08</month><year>2024</year></pub-date><volume>13</volume><issue>3</issue><fpage>117</fpage><lpage>125</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Мандрик М.А., Садковский И.А., Пинегина Е.Д., Король Л.А., Краснюк И.И., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Мандрик М.А., Садковский И.А., Пинегина Е.Д., Король Л.А., Краснюк И.И.</copyright-holder><copyright-holder xml:lang="en">Mandrik M.A., Sadkovskii I.A., Pinegina E.D., Korol L.A., Krasnuk I.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmjournal.ru/jour/article/view/1892">https://www.pharmjournal.ru/jour/article/view/1892</self-uri><abstract><sec><title>Введение</title><p>Введение. Дарунавир, являясь эффективным средством антиретровирусной терапии, широко применяется в клинической практике, в том числе для лечения педиатрических пациентов и беременных женщин, а также в качестве инструмента персонализированной терапии. При этом в производстве готовых лекарственных форм в настоящее время используется дарунавир как в виде кристаллического этанолата, так и в форме аморфной субстанции. В связи с этим существует потребность в разработке и совершенствовании методов количественного определения дарунавира. В качестве недорогой и эффективной альтернативы распространенным хроматографическим и титриметрическим методам может быть использовано спектрофотометрическое определение дарунавира в ультрафиолетовой области спектра (УФ-спектрофотометрия).</p></sec><sec><title>Цель</title><p>Цель. Разработать и валидировать методику количественного определения аморфного дарунавира в субстанции методом УФ-спектрофотометрии.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Для исследования использовали следующие субстанции и расходные материалы: субстанцию-порошок дарунавира аморфного (USP); стандартный образец дарунавира (MSN Pharmachem Pvt. Ltd., Индия); метанол, класс «ос.ч.», для градиентной ВЭЖХ 99,9 %; ацетонитрил для градиентной ВЭЖХ 99,9 %; уксусная кислота (ледяная) для ВЭЖХ; 0,1 моль/л раствор хлорной кислоты в безводной уксусной кислоте для титрования в неводных средах; нейлоновые шприцевые фильтры с диаметром пор 0,22 мкм. Спектрофотометрическое определение дарунавира проводили, используя спектрофотометр Cary 60 (Agilent Technologies, США) и спектрофотометр UNICO 2800 (United Products &amp; Instruments, Inc., США). Для изготовления стандартных растворов использовали весы аналитические Analytical Balance MS105/A (METTLER TOLEDO, Швейцария), весы аналитические GH-120 (AND, Япония), мерную посуду класса А, градуированные пипетки ISOLAB.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. Методика была разработана и валидирована по следующим характеристикам: специфичности, линейности, правильности, прецизионности, аналитической области. По результатам исследования основные валидационные характеристики метода соответствуют критериям приемлемости.</p></sec><sec><title>Заключение</title><p>Заключение. Была проведена успешная разработка и валидация новой методики количественного определения аморфного дарунавира методом УФ-спектрофотометрии. Методика может быть использована для проведения контроля качества субстанций, действующим веществом которых является аморфный дарунавир, в том числе для внутриаптечного контроля.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. Darunavir as an effective antiretroviral drug is widely used in clinical practice, including for the treatment of pediatric patients, as well as pregnant women, and for personalized therapy. Currently darunavir is used in the production of finished dosage forms, both in the form of crystalline ethanolate and in the form of an amorphous substance. In this regard, there is a need to develop and improve methods for the quantitative determination of darunavir. As an inexpensive and effective alternative to common chromatographic and titrimetric methods, spectrophotometric determination of darunavir in the ultraviolet region of the spectrum (UV spectrophotometry) may be used.</p></sec><sec><title>Aim</title><p>Aim. To develop and validate a method for the quantitative determination of amorphous darunavir in the substance by UV spectrophotometry.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. The following substances and consumables were used for the research: powdered amorphous darunavir substance (USP); darunavir reference standard (MSN Pharmachem Pvt. Ltd., India); methanol for HPLC Gradient Grade 99.9 % (High purity); acetonitrile for HPLC Gradient Grade 99.9 %; glacial acetic acid for HPLC; 0.1 M perchloric acid solution (in anhydrous acetic acid) for titration in non-aqueous media; nylon syringe filters with a pore diameter of 0.22 microns. Spectrophotometric determination of darunavir was carried out using an Cary 60 spectrophotometer (Agilent Technologies, USA) and a UNICO 2800 spectrophotometer (United Products &amp; Instruments, Inc., USA). To prepare standard solutions, we used analytical balance Analytical Balance MS105/A (METTLER TOLEDO, Switzerland), analytical balance GH-120 (AND, Japan) class A measuring glassware, graduated pipettes ISOLAB.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. The method was developed and validated for the following characteristics: specificity, linearity, accuracy, precision, analytical range. According to the study results, the main validation characteristics of the method meet the acceptance criteria.</p></sec><sec><title>Conclusion</title><p>Conclusion. A new method for the quantitative determination of amorphous darunavir by UV spectrophotometry was successfully developed and validated. The method may be used to control the quality of substances of amorphous darunavir, including the intrapharmaceutical control.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>аморфный дарунавир</kwd><kwd>УФ-спектрофотометрия</kwd><kwd>валидация</kwd><kwd>специфичность</kwd><kwd>линейность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>amorphous darunavir</kwd><kwd>UV spectrophotometry</kwd><kwd>validation</kwd><kwd>specificity</kwd><kwd>linearity</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">McKeage K., Perry C. M., Keam S. J. Darunavir: a review of its use in the management of HIV infection in adults. Drugs. 2009;69:477–503. DOI: 10.2165/00003495-200969040-00007.</mixed-citation><mixed-citation xml:lang="en">McKeage K., Perry C. M., Keam S. J. Darunavir: a review of its use in the management of HIV infection in adults. Drugs. 2009;69:477–503. DOI: 10.2165/00003495-200969040-00007.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Y., Lv Z., Chu Y. HIV protease inhibitors: a review of molecular selectivity and toxicity. HIV/AIDS – Research and Palliative Care. 2015;7:95–104. DOI: 10.2147/hiv.s79956.</mixed-citation><mixed-citation xml:lang="en">Wang Y., Lv Z., Chu Y. HIV protease inhibitors: a review of molecular selectivity and toxicity. HIV/AIDS – Research and Palliative Care. 2015;7:95–104. DOI: 10.2147/hiv.s79956.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Lascar R., Benn P. Role of darunavir in the management of HIV infection. HIV/AIDS – Research and Palliative Care. 2009;1:31–39. DOI: 10.2147/hiv.s5397.</mixed-citation><mixed-citation xml:lang="en">Lascar R., Benn P. Role of darunavir in the management of HIV infection. HIV/AIDS – Research and Palliative Care. 2009;1:31–39. DOI: 10.2147/hiv.s5397.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Saag M. S., Gandhi R. T., Hoy J. F., Landovitz R. J., Thompson M. A., Sax P. E., Smith D. M., Benson C. A., Buchbinder S. P., del Rio C., Eron J. J. Jr., Fätkenheuer G., Günthard H. F., Molina J.-M., Jacobsen D. M., Volberding P. A. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. 2020 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2020;324(16):1651–1669. DOI: 10.1001/jama.2020.17025.</mixed-citation><mixed-citation xml:lang="en">Saag M. S., Gandhi R. T., Hoy J. F., Landovitz R. J., Thompson M. A., Sax P. E., Smith D. M., Benson C. A., Buchbinder S. P., del Rio C., Eron J. J. Jr., Fätkenheuer G., Günthard H. F., Molina J.-M., Jacobsen D. M., Volberding P. A. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. 2020 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2020;324(16):1651–1669. DOI: 10.1001/jama.2020.17025.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Keating G. M. Darunavir: A Review in Pediatric HIV-1 Infection. Paediatr Drugs. 2015;17(5):411–421. DOI: 10.1007/s40272-015-0146-0.</mixed-citation><mixed-citation xml:lang="en">Keating G. M. Darunavir: A Review in Pediatric HIV-1 Infection. Paediatr Drugs. 2015;17(5):411–421. DOI: 10.1007/s40272-015-0146-0.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Pope R. Jr., Kashuba A. Darunavir for use in pregnant women with HIV. Expert Review of Clinical Pharmacology. 2017; 10(12):1317–1327. DOI: 10.1080/17512433.2017.1390428.</mixed-citation><mixed-citation xml:lang="en">Pope R. Jr., Kashuba A. Darunavir for use in pregnant women with HIV. Expert Review of Clinical Pharmacology. 2017; 10(12):1317–1327. DOI: 10.1080/17512433.2017.1390428.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">King N. M., Prabu-Jeyabalan M., Nalivaika E. A., Wigerinck P., de Béthune M.-P., Schiffer C. A. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. Journal of Virology. 2004;78(21):12012–12021. DOI: 10.1128/jvi.78.21.12012-12021.2004.</mixed-citation><mixed-citation xml:lang="en">King N. M., Prabu-Jeyabalan M., Nalivaika E. A., Wigerinck P., de Béthune M.-P., Schiffer C. A. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. Journal of Virology. 2004;78(21):12012–12021. DOI: 10.1128/jvi.78.21.12012-12021.2004.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Tremblay C. L. Combating HIV resistance – focus on darunavir. Therapeutics and Clinical Risk Management. 2008;4(4):759–765. DOI: 10.2147/tcrm.s1709.</mixed-citation><mixed-citation xml:lang="en">Tremblay C. L. Combating HIV resistance – focus on darunavir. Therapeutics and Clinical Risk Management. 2008;4(4):759–765. DOI: 10.2147/tcrm.s1709.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Cusato J., Allegra S., de Nicolò A., Calcagno A., D’Avolio A. Precision medicine for HIV: where are we? Pharmacogenomics. 2018;19(2):145–165. DOI: 10.2217/pgs-2017-0123.</mixed-citation><mixed-citation xml:lang="en">Cusato J., Allegra S., de Nicolò A., Calcagno A., D’Avolio A. Precision medicine for HIV: where are we? Pharmacogenomics. 2018;19(2):145–165. DOI: 10.2217/pgs-2017-0123.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Zolotov S. A., Dain I. A., Demina N. B., Zolotova A. S., Ponomarev E. S. The Effect of Solvents and Drying Temperature on the Physicochemical Properties of Darunavir and Darunavir Ethanolate Substances. Drug development &amp; registration. 2021;10(1):67–73. (In Russ.) DOI: 10.33380/2305-2066-2021-10-1-67-73.</mixed-citation><mixed-citation xml:lang="en">Zolotov S. A., Dain I. A., Demina N. B., Zolotova A. S., Ponomarev E. S. The Effect of Solvents and Drying Temperature on the Physicochemical Properties of Darunavir and Darunavir Ethanolate Substances. Drug development &amp; registration. 2021;10(1):67–73. (In Russ.) DOI: 10.33380/2305-2066-2021-10-1-67-73.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Van Gyseghem E., Stokbroekx S., de Armas H. N., Dickens J., Vanstockem M., Baert L., Rosier J., Schueller L., Van den Mooter G. Solid state characterization of the anti-HIV drug TMC114: interconversion of amorphous TMC114, TMC114 ethanolate and hydrate. European Journal of Pharmaceutical Sciences. 2009;38(5):489–497. DOI: 10.1016/j.ejps.2009.09.013.</mixed-citation><mixed-citation xml:lang="en">Van Gyseghem E., Stokbroekx S., de Armas H. N., Dickens J., Vanstockem M., Baert L., Rosier J., Schueller L., Van den Mooter G. Solid state characterization of the anti-HIV drug TMC114: interconversion of amorphous TMC114, TMC114 ethanolate and hydrate. European Journal of Pharmaceutical Sciences. 2009;38(5):489–497. DOI: 10.1016/j.ejps.2009.09.013.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Kavitha A. N., Raman D., Janaki R. K. A New Validated RP-HPLC Method for the Estimation of Darunavir Ethanolate in Bulk and Tablets. Asian Journal of Pharmaceutics (AJP). 2020;14(4):652–660.</mixed-citation><mixed-citation xml:lang="en">Kavitha A. N., Raman D., Janaki R. K. A New Validated RP-HPLC Method for the Estimation of Darunavir Ethanolate in Bulk and Tablets. Asian Journal of Pharmaceutics (AJP). 2020;14(4):652–660.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Paul K., Jaswanth Gowda B. H., Shankar, S. J., Reddy D. N. Development and validation of simplified RP-HPLC method for quantification of Darunavir in commercial tablets. Materials Today: Proceedings. 2021;47(14):4155–4161. DOI: 10.1016/j.matpr.2021.04.444.</mixed-citation><mixed-citation xml:lang="en">Paul K., Jaswanth Gowda B. H., Shankar, S. J., Reddy D. N. Development and validation of simplified RP-HPLC method for quantification of Darunavir in commercial tablets. Materials Today: Proceedings. 2021;47(14):4155–4161. DOI: 10.1016/j.matpr.2021.04.444.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Rao K. P., Ramesh B. V., Prasad C. S., Ramana G. V., Rao M. C. Validated isocratic reversed phase liquid chromatographic method for the determination of darunavir in pure and formulations. Der Pharmacia Lettre. 2016;8(10):222–228.</mixed-citation><mixed-citation xml:lang="en">Rao K. P., Ramesh B. V., Prasad C. S., Ramana G. V., Rao M. C. Validated isocratic reversed phase liquid chromatographic method for the determination of darunavir in pure and formulations. Der Pharmacia Lettre. 2016;8(10):222–228.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Reddy B. V. R., Jyothi G., Reddy B. S., Raman N. V. V. S. S., Reddy K. S. C., Rambabu C. Stability-indicating HPLC method for the determination of darunavir ethanolate. Journal of Chromatographic Science. 2013;51(5):471–476. DOI: 10.1093/chromsci/bms165.</mixed-citation><mixed-citation xml:lang="en">Reddy B. V. R., Jyothi G., Reddy B. S., Raman N. V. V. S. S., Reddy K. S. C., Rambabu C. Stability-indicating HPLC method for the determination of darunavir ethanolate. Journal of Chromatographic Science. 2013;51(5):471–476. DOI: 10.1093/chromsci/bms165.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Mantena B. P. V., Rao S. V., Appa Rao K. M. C., Ramakrishna K., Reddy R. S. Method development and validation for the determination of four potential impurities present in darunavir tablets by reverse phase–ultra-performance liquid chromatography coupled with diode-array detector. Journal of Liquid Chromatography &amp; Related Technologies. 2015;38(12):1236–1246. DOI: 10.1080/10826076.2015.1037449.</mixed-citation><mixed-citation xml:lang="en">Mantena B. P. V., Rao S. V., Appa Rao K. M. C., Ramakrishna K., Reddy R. S. Method development and validation for the determination of four potential impurities present in darunavir tablets by reverse phase–ultra-performance liquid chromatography coupled with diode-array detector. Journal of Liquid Chromatography &amp; Related Technologies. 2015;38(12):1236–1246. DOI: 10.1080/10826076.2015.1037449.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Timchenko Yu. V. Advantages and disadvantages of high-performance liquid chromatography (HPCL). Journal of Environmental Analytical Chemistry. 2021;8(10):335.</mixed-citation><mixed-citation xml:lang="en">Timchenko Yu. V. Advantages and disadvantages of high-performance liquid chromatography (HPCL). Journal of Environmental Analytical Chemistry. 2021;8(10):335.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Kogawa A. C., Salgado H. R. N. Development and validation of infrared spectroscopy method for the determination of darunavir in tablets. Physical Chemistry. 2013;3(1):1–6. DOI: 10.5923/j.pc.20130301.01.</mixed-citation><mixed-citation xml:lang="en">Kogawa A. C., Salgado H. R. N. Development and validation of infrared spectroscopy method for the determination of darunavir in tablets. Physical Chemistry. 2013;3(1):1–6. DOI: 10.5923/j.pc.20130301.01.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Kogawa A. C., Aguiar F. A., Gaitani C. M., Salgado H. R. N. Validation of a stability indicating capillary electrophoresis method for the determination of darunavir in tablets and comparison with the of infrared absorption spectroscopic method. World Journal of Pharmacy and Pharmaceutical Sciences. 2014;3:283–297.</mixed-citation><mixed-citation xml:lang="en">Kogawa A. C., Aguiar F. A., Gaitani C. M., Salgado H. R. N. Validation of a stability indicating capillary electrophoresis method for the determination of darunavir in tablets and comparison with the of infrared absorption spectroscopic method. World Journal of Pharmacy and Pharmaceutical Sciences. 2014;3:283–297.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Patel B., Suhagia B., Patel C., Panchal H. A simple and sensitive HPTLC method for quantitative analysis of darunavir ethanolate tablets. Journal of Planar Chromatography – Modern TLC. 2011;24(3):232–235. DOI: 10.1556/jpc.24.2011.3.11.</mixed-citation><mixed-citation xml:lang="en">Patel B., Suhagia B., Patel C., Panchal H. A simple and sensitive HPTLC method for quantitative analysis of darunavir ethanolate tablets. Journal of Planar Chromatography – Modern TLC. 2011;24(3):232–235. DOI: 10.1556/jpc.24.2011.3.11.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Ghante M., Shelar R. S., Sawant S., Kadam M. M. Development and validation of UV spectrophotometric method for estimation of darunavir ethanolate in bulk and tablet dosage form. International Journal of Pharmacy and Pharmaceutical Sciences. 2014;6(7):240–242.</mixed-citation><mixed-citation xml:lang="en">Ghante M., Shelar R. S., Sawant S., Kadam M. M. Development and validation of UV spectrophotometric method for estimation of darunavir ethanolate in bulk and tablet dosage form. International Journal of Pharmacy and Pharmaceutical Sciences. 2014;6(7):240–242.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Singh V. D., Singh V. K. Chemo-metric assisted UV-spectrophotometric methods for simultaneous estimation of Darunavir ethanolate and Cobicistat in binary mixture and their tablet formulation. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2021;250:119383. DOI: 10.1016/j.saa.2020.119383.</mixed-citation><mixed-citation xml:lang="en">Singh V. D., Singh V. K. Chemo-metric assisted UV-spectrophotometric methods for simultaneous estimation of Darunavir ethanolate and Cobicistat in binary mixture and their tablet formulation. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2021;250:119383. DOI: 10.1016/j.saa.2020.119383.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Rao P. K. Validation of Visible Spectrophotometric Methods of Darunavir in Pure and Dosage Forms. Der Pharma Chemica. 2016;8(17):54–61.</mixed-citation><mixed-citation xml:lang="en">Rao P. K. Validation of Visible Spectrophotometric Methods of Darunavir in Pure and Dosage Forms. Der Pharma Chemica. 2016;8(17):54–61.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Rajendran V., Ramya Y. N. S., Mani A. D., Dhanaraju M. D. Spectrophotometric determination of darunavir ethanolate by condensation technique. International Journal of PharmTech Research. 2016;9(6):301–306.</mixed-citation><mixed-citation xml:lang="en">Rajendran V., Ramya Y. N. S., Mani A. D., Dhanaraju M. D. Spectrophotometric determination of darunavir ethanolate by condensation technique. International Journal of PharmTech Research. 2016;9(6):301–306.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Krishna Kumar Rao K. V. V., Phanindra B., Rajesh K. Spectrophotometric method for estimation of darunavir ethanolate by using MBTH reagent in bulk and pharmaceutical dosage form. Inventi Rapid. 2013;4:1–3.</mixed-citation><mixed-citation xml:lang="en">Krishna Kumar Rao K. V. V., Phanindra B., Rajesh K. Spectrophotometric method for estimation of darunavir ethanolate by using MBTH reagent in bulk and pharmaceutical dosage form. Inventi Rapid. 2013;4:1–3.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Nageswara Rao R., Ramachandra B., Sravan B., Khalid S. LC-MS/MS structural characterization of stress degradation products including the development of a stability indicating assay of Darunavir: An anti-HIV drug. Journal of Pharmaceutical and Biomedical Analysis. 2014;89:28–33. DOI: 10.1016/j.jpba.2013.10.007.</mixed-citation><mixed-citation xml:lang="en">Nageswara Rao R., Ramachandra B., Sravan B., Khalid S. LC-MS/MS structural characterization of stress degradation products including the development of a stability indicating assay of Darunavir: An anti-HIV drug. Journal of Pharmaceutical and Biomedical Analysis. 2014;89:28–33. DOI: 10.1016/j.jpba.2013.10.007.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Modini A. K., Ranga M., Puppala U., Kaliyapermal M., Geereddy M. K. R., Samineni R., Grover P., Konidala S. K. Identification, Isolation, and Structural Characterization of Novel Forced Degradation Products of Darunavir Using Advanced Analytical Techniques Like UPLC-MS, Prep-HPLC, HRMS, NMR, and FT-IR Spectroscopy. Chromatographia. 2023;86(1):63–78. DOI: 10.1007/s10337-022-04226-z.</mixed-citation><mixed-citation xml:lang="en">Modini A. K., Ranga M., Puppala U., Kaliyapermal M., Geereddy M. K. R., Samineni R., Grover P., Konidala S. K. Identification, Isolation, and Structural Characterization of Novel Forced Degradation Products of Darunavir Using Advanced Analytical Techniques Like UPLC-MS, Prep-HPLC, HRMS, NMR, and FT-IR Spectroscopy. Chromatographia. 2023;86(1):63–78. DOI: 10.1007/s10337-022-04226-z.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
